All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
strong>Aerie Pharmaceuticals Inc., of Irvine, Calif., said the FDA has agreed in written and verbal communications that it may change the primary endpoint range of its second phase III registration trial of Rhopressa, named Rocket 2, to include patients with baseline intraocular pressures (IOPs) ranging from above 20 mmHg to below 25 mmHg.